Camurus
482.20 SEK
-0.25 %
Less than 1K followers
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.25 %
-28.14 %
-21.72 %
-20.17 %
-33.35 %
-23.52 %
+109.83 %
+117.70 %
+698.00 %
Camurus operates in biotechnology. The company is operated as a research-based pharmaceutical company that develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders and patients with opioid addiction. Camurus runs development projects under its own management and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Read moreMarket cap
28.9B SEK
Turnover
39.83M SEK
Revenue
2.27B
EBIT %
38.58 %
P/E
38.82
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.5
2026
Interim report Q1'26
28.5
2026
General meeting '26
15.7
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Redeye: Camurus (Q4 review): Temporary UK Setback
Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
